论文部分内容阅读
目的观察支气管哮喘(bronchial asthma,BA)患者经过短期沙美特罗替卡松吸入剂(salmeterol and fluticasone propionate inhalation,SFPI)治疗后气道高反应性(airway hyperresponsiveness,AHR)的变化。方法收集80例BA患者,随机分成治疗组、对照组,每组各40例。对照组给予氨茶碱、酮替芬,治疗组在对照组基础上加用SFPI,疗程为15～30 d。两组患者在治疗前给予乙酰甲胆碱激发试验(methacholine challenge test,MCT)测定,停药48 h后复查MCT。结果治疗组与对照组在治疗前MCT阳性率分别为97.5%和97.5%;治疗后MCT阳性率分别为70.0%和90.0%。治疗前两组间比较差异无统计学意义(P>0.05);治疗后两组间比较差异有统计学意义(P<0.05)。治疗组与对照组治疗后Dmin,PD35,Cmin比较差异有统计学意义(P<0.05)。治疗组Dmin,PD35,Cmin在治疗后与治疗前比较差异有统计学意义(P<0.05)。结论 SFPI能降低BA患者的AHR。
Objective To observe the changes of airway hyperresponsiveness (AHR) in patients with bronchial asthma (BA) treated with short-term salmeterol and fluticasone propionate inhalation (SFPI). Methods Eighty BA patients were collected and randomly divided into treatment group and control group, 40 cases in each group. The control group was treated with aminophylline and ketotifen, and the treatment group was given SFPI on the basis of the control group for 15-30 days. The two groups were given methacholine challenge test (MCT) before treatment, MCT was checked after 48 hours withdrawal. Results The positive rates of MCT before treatment in treatment group and control group were 97.5% and 97.5%, respectively. The positive rates of MCT after treatment were 70.0% and 90.0% respectively. There was no significant difference between the two groups before treatment (P> 0.05). There was significant difference between the two groups after treatment (P <0.05). The difference of Dmin, PD35 and Cmin between the treatment group and the control group after treatment was statistically significant (P <0.05). The treatment group Dmin, PD35, Cmin after treatment compared with before treatment was statistically significant (P <0.05). Conclusion SFPI can reduce the AHR in patients with BA.